[go: up one dir, main page]

BR9815745A - Combinations of statin matrix metalloproteinase inhibitor - Google Patents

Combinations of statin matrix metalloproteinase inhibitor

Info

Publication number
BR9815745A
BR9815745A BR9815745-0A BR9815745A BR9815745A BR 9815745 A BR9815745 A BR 9815745A BR 9815745 A BR9815745 A BR 9815745A BR 9815745 A BR9815745 A BR 9815745A
Authority
BR
Brazil
Prior art keywords
statin
combinations
matrix metalloproteinase
metalloproteinase inhibitor
inhibitor
Prior art date
Application number
BR9815745-0A
Other languages
Portuguese (pt)
Inventor
Roger Schofield Newton
Bruce David Roth
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9815745A publication Critical patent/BR9815745A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>"COMBINAçõES DE INIBIDOR DE METALOPROTEINASE DE MATRIZ ESTATINA"<D>. A invenção é uma composição farmacêutica compreendendo um inibidor MMP e uma estatina, a dita composição sendo útil para tratamento de doenças vasculares.Invention Patent: <B> "STATINE MATRIX METALOPROTEINASE INHIBITOR COMBINATIONS" <D>. The invention is a pharmaceutical composition comprising an MMP inhibitor and a statin, said composition being useful for treating vascular diseases.

BR9815745-0A 1998-03-17 1998-11-20 Combinations of statin matrix metalloproteinase inhibitor BR9815745A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17
PCT/US1998/024681 WO1999047138A1 (en) 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations

Publications (1)

Publication Number Publication Date
BR9815745A true BR9815745A (en) 2000-11-14

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815745-0A BR9815745A (en) 1998-03-17 1998-11-20 Combinations of statin matrix metalloproteinase inhibitor

Country Status (18)

Country Link
EP (1) EP1063991A1 (en)
JP (1) JP2002506818A (en)
KR (1) KR20010041916A (en)
AR (1) AR018113A1 (en)
AU (1) AU1591699A (en)
BR (1) BR9815745A (en)
CA (1) CA2309588A1 (en)
CO (1) CO5070670A1 (en)
GT (1) GT199900039A (en)
HN (1) HN1999000029A (en)
MY (1) MY140504A (en)
NZ (1) NZ505994A (en)
PA (1) PA8469001A1 (en)
PE (1) PE20000348A1 (en)
SV (1) SV1999000026A (en)
UY (1) UY25436A1 (en)
WO (1) WO1999047138A1 (en)
ZA (1) ZA992106B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
AU2005315608B2 (en) 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
JP2009514851A (en) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド (3R, 5R) -7- [2- (4-Fluorophenyl) -5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino) carbonyl] -pyrrol-1-yl] -3,5 -Preparation of dihydroxy-heptanoic acid hemi-calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123902A (en) * 1995-11-02 2003-01-12 Warner Lambert Co PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR
ES2167733T3 (en) * 1996-05-17 2002-05-16 Warner Lambert Co BIFENYLSULFONAMIDE MATRIX METALOPROTEINASE INHIBITORS.
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.

Also Published As

Publication number Publication date
WO1999047138A1 (en) 1999-09-23
MY140504A (en) 2009-12-31
ZA992106B (en) 1999-09-30
UY25436A1 (en) 2001-10-25
CO5070670A1 (en) 2001-08-28
KR20010041916A (en) 2001-05-25
EP1063991A1 (en) 2001-01-03
PE20000348A1 (en) 2000-05-22
GT199900039A (en) 2000-09-06
PA8469001A1 (en) 2002-09-17
AR018113A1 (en) 2001-10-31
NZ505994A (en) 2003-10-31
JP2002506818A (en) 2002-03-05
HN1999000029A (en) 1999-09-29
SV1999000026A (en) 2000-01-18
AU1591699A (en) 1999-10-11
CA2309588A1 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
BR0113669A (en) Deacetylase Inhibitors
BR9809793A (en) Probucol monoesters for the treatment of inflammatory and cardiovascular disease
BR9805544C1 (en) Use of a compound.
AR032086A1 (en) PHARMACOS COMBINATIONS
BR0212014A (en) Use of hydroxamic acid derivatives histone deacetylase inhibitors
PA8506101A1 (en) USE OF AN ACAT COMPOUND TO MANUFACTURE A PHARMACEUTICAL COMPOSITION
FI940012A0 (en) Arylsufonamidosubstituted hydroxamic acids
BR9812753A (en) Pharmaceutical combination, use thereof, process for treating an inflammatory disease, and pharmaceutical composition
MA26812A1 (en) PYRIMIDINE-2,4,6-TRIONES INHIBITORS OF METALLOPROTEINASES
EP1496906A4 (en) INHIBITORS OF AKT ACTIVITY
EP1494675A4 (en) INHIBITORS OF AKT ACTIVITY
BR0317715A (en) Compositions and processes of use of collajolie
ATE266000T1 (en) HYDROXAMIC ACID AND CARBOXIC ACID DERIVATIVES WITH MMP AND TNF INHIBITING EFFECTS
BR9807655A (en) Use of gastrointestinal lipase inhibitors.
BR9711194A (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer&#39;s disease.
NO973035D0 (en) Hydroxamic acid-containing inhibitors of matrix metal proteases
EE200000093A (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
BR9812371A (en) Treatment of conduct disorder
ATE266634T1 (en) CYCLOBUTYL-ARYLOXYSULFONYLAMIN HYDROXAMIC ACID DERIVATIVES
BR9812357A (en) Challenging oppositional disorder treatment
FR2834890B1 (en) ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF AGOMELATIN
BR9714142A (en) Use of matrix metalloproteinase inhibitors to treat neurological disorders and promote wound healing
EA200401183A1 (en) APPLICATION OF IL-18 INHIBITORS AS A DIAGNOSTIC MARKER
BR9804027A (en) New beta-keto esters
ATE448774T1 (en) COSMETIC COMPOSITION CONTAINING A SIEGESBECKIA EXTRACT AND A LIPOPEPTIDE

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 45/06, A61P 9/10

Ipc: A61K 31/40 (2008.04)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.